Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 10000 participants.

Also called NCT01924325

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 10,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01924325
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01924325. Randomized; triple masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2015-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events
Acronym
ADANCE
Intervention (Drug)
Apixaban
Intervention (Drug)
Clopidogrel
Intervention (Drug)
Aspirin
Intervention (Drug)
placebo
Lead sponsor
Xijing Hospital (class: other)

Record details

Record id
cardio:ct-nct01924325
Content hash
fb266168078ffd3bfeb30452224425656889fc2b5066bc01c42cd7ccdbd75f5a